Search Results

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has appointed John Orwin chairman of the AnaptysBio Board of Directors.

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, and Dr. Paul Lizzul, chief medical officer, will present at the Stifel 2023 Immunology and Inflammation Virtual Summit later this month.

AnaptysBio, Inc. announced that Daniel Faga, interim president and chief executive officer of AnaptysBio, and other members of its senior management team are scheduled to participate in both of the upcoming investor conferences below:

The company’s experimental lgG4 antibody met the primary endpoint in a late-stage study of the rare skin disease. AnaptysBio will submit an application to the FDA by the third quarter of 2024.

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the second quarter ended June 30, 2023 and provided a business update.

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the first quarter ended March 31, 2023 and provided pipeline updates.

AnaptysBio, Inc., a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced the appointment of Rita Jain, M.D., to the company’s Board of Directors, effective immediately.

AnaptysBio, Inc. today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $50,000,000 of the Company’s outstanding common stock, par value $0.001 per share.

AnaptysBio, Inc. (Nasdaq: ANAB) today announced that GSK has received U.S. Food and Drug Administration (FDA) approval for JEMPERLI (dostarlimab-gxly) plus carboplatin and paclitaxel (chemotherapy) for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer.

AnaptysBio, Inc., a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced the execution of an amended agreement with Sagard Healthcare for additional Anaptys Jemperli royalties.